Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Aleksandra Plavsic; Rada Miskovic; Sanvila Raskovic; Mirjana Bogic; Branka Bonaci Nikolic

doi:10.3889/oamjms.2014.098

Authors

Aleksandra Plavsic Clinical Center of Serbia, Clinic for Allergology and Immunology, Belgrade
Rada Miskovic Clinical Center of Serbia, Clinic for Allergology and Immunology, Belgrade
Sanvila Raskovic Clinical Center of Serbia, Clinic for Allergology and Immunology, School of Medicine, University of Belgrade, Belgrade
Mirjana Bogic Clinical Center of Serbia, Clinic for Allergology and Immunology, School of Medicine, University of Belgrade, Belgrade
Branka Bonaci Nikolic Clinical Center of Serbia, Clinic for Allergology and Immunology, School of Medicine, University of Belgrade, Belgrade

DOI:

https://doi.org/10.3889/oamjms.2014.098

Keywords:

antiphospholipid syndrome, systemic lupus erythematosus, antiphospholipid antibodies, thrombosis, anticoagulant therapy.

Abstract

Antiphospholipid syndrome is an autoimmune disorder defined as association of vascular thrombosis and/or pregnancy complications with presence of antiphospholipid antibodies (lupus anticoagulant, anticardiolipin and anti-Î²2 glycoprotein I). It is the most common cause of acquired thrombophilia, and can occur as an independent entity or in relation with other diseases, especially systemic lupus erythematosus. Presence of antiphospholipid syndrome in systemic lupus erythematosus is additional vaso occlusive factor in already present inflammation, bringing further risk for thrombotic events. Clinical and serological manifestations of antiphospholipid syndrome and systemic lupus erythematosus are very similar, so possible connection for these two autoimmune disorders is assumed.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definitive antiphosholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306. DOI: https://doi.org/10.1111/j.1538-7836.2006.01753.x

Asherson RA, Cervera R, de Groot PG. Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530-534. DOI: https://doi.org/10.1191/0961203303lu394oa

Pengo V, Banzato A, Bison E, Denas G, Padayattil JS, Ruffatti A. Antiphospholipid syndrome: critical analysis of the diagnostic path. Lupus. 2010;19:428-431. DOI: https://doi.org/10.1177/0961203309360543

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. DOI: https://doi.org/10.1002/art.1780400928

ElezoviÄ‡ I, MiljiÄ‡ P, AntunoviÄ‡ P, SuvajdziÄ‡ N, SretenoviÄ‡ M, ColoviÄ‡ M. The management of antiphospholipid syndrome. Vojnosanit Pregl. 1998;55(2 Suppl):41-6.

Weber M, Hayem G, de Bandt M, et al. Classification of an intermediate group of patients with antiphosholipid syndrome and lupus-like disease:primary or secondary antiphosholipid syndrome? J Rheumatol. 1999;26:2131-2136.

Espinosa G, Cervera R. Antiphosholipid syndrome. Arthritis Res Ther. 2008;10:230. DOI: https://doi.org/10.1186/ar2536

Urbanus RT, Derksen RH, de Groot PG. Current insight into diagnosis and pathophysiology of the antiphosholpid syndrome. Blood Rev. 2008;22:93-105. DOI: https://doi.org/10.1016/j.blre.2007.09.001

Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368:1033-44. DOI: https://doi.org/10.1056/NEJMra1112830

Comarmond C, Cacoub P. Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Autoimmun Rev. 2013;12(7):752-7. DOI: https://doi.org/10.1016/j.autrev.2012.12.006

The black box and Du VX, Kelchtermans H, de Groot PG, de Laat B. From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: pathogenic mechanisms of the antiphospholipid syndrome. Thromb Res. 2013; 132(3):319-26. DOI: https://doi.org/10.1016/j.thromres.2013.07.023

GirardiG. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112: 1644-54. DOI: https://doi.org/10.1172/JCI200318817

Gropp K, Weber N, Reuter M, Micklisch S, Kopka I, HallstromT, et al. Beta(2)-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood. 2011;118(10):2774â€“83. DOI: https://doi.org/10.1182/blood-2011-02-339564

Canaud G, Kamar N, Anglicheau D, Esposito L, Rabant M, Noel LH, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant. 2013;13:2179-85. DOI: https://doi.org/10.1111/ajt.12319

Laskin CA, Clark CA, Spitzer KA. Antiphosholipid syndrome in systemic lupus erytematosus: Is the whole greater then the sum of its parts? Rheum Dise North Am. 2005;31:255-272. DOI: https://doi.org/10.1016/j.rdc.2005.01.011

McClain MT, Arbuckle MR, Heinlen LD, Dennis GJ, Roebuck J, Rubertone MV, Harley JB, James JA. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum. 2004;50:1226-1232.

Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, et al. Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-1027. DOI: https://doi.org/10.1002/art.10187

Merrill JT. Diagnosis of the antiphospholipid syndrome: how far to go? Curr Rheumatol Rep. 2004;6:469-472. DOI: https://doi.org/10.1007/s11926-004-0027-y

Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune diseases: a meta-analysis. J Rheumatol. 2006;33:2214-2221.

Parkpian V, Verasertniyom O, Vanichapuntu M, Totemchokchyakarn K, Nantiruj K, Pisitkul P, Angchaisuksiri P, Archararit N, Rachakom B, Ayurachai K, Janwityanujit S. Specificity and sensitivity of anti-beta2-glycoprotein I as compared with anticardiolipin antibody and lupus anticoagulant in Thai systemic lupus erythematosus patients with clinical features of antiphospholipid syndrome. Clin Rheumatol. 2007;26:1663-1670. DOI: https://doi.org/10.1007/s10067-007-0566-5

Sweiss NJ, Bo R, Kapadia R, Manst D, Mahmood F, Adhikari T, Volkov S, Badaracco M, Smaron M, Chang A, Baron J, Levine JS. IgA anti beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. Plos One. 2010;5(8):e12280. DOI: https://doi.org/10.1371/journal.pone.0012280

Bertolaccini ML, Amengual O, Atsumi T, Binder WL, de Laat B, Forastiero R, Kutteh WH, Lambert M, Matsubayashi H, Murthy V, Petri M, Rand JH, Sanmarco M, Tebo AE, Pierangeli SS. Non-criteria aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus. 2011;20:191-205. DOI: https://doi.org/10.1177/0961203310397082

Mchrani T, Petri M. Epidemiology of the antiphospholipid syndrome. In: Asherson RA, Handbook of systemic autoimmune diseases, Pa:Elsevier;2009. DOI: https://doi.org/10.1016/S1571-5078(08)00402-9

Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A, et al. Comparison of the primary and secondary antiphospholipid syndrome: A European multicenter study of 114 patients. Am J Med. 1994;96:3-9. DOI: https://doi.org/10.1016/0002-9343(94)90108-2

De Groot PG, Horbach DA, SimmelinkMJ, van Oort E, Derksen RH. Anti-prothrombin antibodies and their relation with thrombosis and lupus anticoagulant. Lupus. 1998;7(Suppl. 2):S32â€“6. DOI: https://doi.org/10.1177/096120339800700208

Sanmarco M, Boffa M-C. Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome. Lupus. 2009;18:920â€“3. DOI: https://doi.org/10.1177/0961203309106920

Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombinantibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood. 2003;102:2717â€“23. DOI: https://doi.org/10.1182/blood-2002-11-3334

Alessandri C, Conti F, Pendolino M, Mancini R, Valesini G. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev. 2011;10:609â€“16. DOI: https://doi.org/10.1016/j.autrev.2011.04.011

Biggioggerro M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev. 2010;9:299-304. DOI: https://doi.org/10.1016/j.autrev.2009.11.013

Lim W. Antiphospholipid antibody syndrome. Hematology Am Soc Hematol Ed Program. 2009:233-239. DOI: https://doi.org/10.1182/asheducation-2009.1.233

Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus antiphospholipid antibodies: prevalence, clinical associations, and longterm outcome. Arthritis Rheum. 2004;50:2569-2579. DOI: https://doi.org/10.1002/art.20433

Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus. 2007;16:39-45. DOI: https://doi.org/10.1177/0961203306074767

Choojitarom K, Verasertniyom O, Totemchokchyakarn K, Nantiruj K, Sumethkul V, Janwityanujit S. Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. Clin Rheumatol. 2008;27:345-351. DOI: https://doi.org/10.1007/s10067-007-0721-z

Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA, Bertolaccini ML. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities.J Thromb Haemost. 2012;10(12):2512-2518. DOI: https://doi.org/10.1111/jth.12014

Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: the global anti-phospholipid syndrome score. Rheumatology (Oxford). 2013;52:1397-1403. DOI: https://doi.org/10.1093/rheumatology/kes388

GÃ³mez-Puerta JA, MartÃn H, Amigo MC, Aguirre MA, Camps MT, Cuadrado MJ, Hughes GR, Khamashta MA. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore). 2005;84:225-230. DOI: https://doi.org/10.1097/01.md.0000172074.53583.ea

Tarr T, Lakos G, Bhattoa HP, Szegedi G, Shoenfeld Y, Kiss E. Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus. Lupus. 2007;16:324-328. DOI: https://doi.org/10.1177/0961203307077993

McClain MT, Arbuckle MR, Heinlen LD, Dennis GJ, Roebuck J, Rubertone MV, Harley JB, James JA. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum. 2004;50:1226-1232. DOI: https://doi.org/10.1002/art.20120

Veres K, Szodoray P, Szekanecz Z, Lakos G, Kiss E, Laczik R, Sipka S, Bodolay E, Zeher M, Muszbek L, Szegedi G, SoltÃ©sz P. Clinical and immunoserological characteristics of the transition from primary to overlap antiphospholipid syndrome. Lupus. 2010;19:1520-1526. DOI: https://doi.org/10.1177/0961203310374336

Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56:2382-2391. DOI: https://doi.org/10.1002/art.22663

Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med. 2000;160:2042-2048. DOI: https://doi.org/10.1001/archinte.160.13.2042

Tuthill JI, Khamashta MA.Management of antiphospholipid syndrome. J Autoimmun. 2009;33(2):92-98. DOI: https://doi.org/10.1016/j.jaut.2009.05.002

Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20â€“8. DOI: https://doi.org/10.1136/ard.2008.101766

Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, Levy RA, Ortel TL, Rahman A, Salmon JE, Tektonidou MG, Willis R, Lockshin MD. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685-96. DOI: https://doi.org/10.1016/j.autrev.2014.01.053

Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295:1050-1057. DOI: https://doi.org/10.1001/jama.295.9.1050

Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498-1509. DOI: https://doi.org/10.1016/S0140-6736(10)60709-X

Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, Erkan D, Krilis S, Machin S, Pengo V, Pierangeli S, Tektonidou M, Khamashta M. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206-218. DOI: https://doi.org/10.1177/0961203310395803

Shoenfeld Y, Meroni PL, Toubi E. Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale? Curr Rheumatol Rep. 2009;21(5):495-500. DOI: https://doi.org/10.1097/BOR.0b013e32832effdd

Mehdi AA, Uthman I, Khamashata M. Antiphosholipid syndrome: pathogenesis and a window of treatment opportunities in the future. Eur J Clin Invest. 2010;40:451-464. DOI: https://doi.org/10.1111/j.1365-2362.2010.02281.x

Redecha P, Tilley R, Tencati M, Salmon JE, Kirchhofer D, Mackman N, Girardi G. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood. 2007;110:2423-2431. DOI: https://doi.org/10.1182/blood-2007-01-070631

Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T, Yahuda S, Koike T. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis. 2009;68:1030-1035. DOI: https://doi.org/10.1136/ard.2008.090670

Agmon-Levin N, Blank M, Zandman-Goddard G, Orbach H, Meroni PL, Tincani A, Doria A, Cervera R, Miesbach W, Stojanovich L, Barak V, Porat-Katz BS, Amital H, Shoenfeld Y. Vitamin D: an instrumental factor in the antiphospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis.2011;70(1):145-150. DOI: https://doi.org/10.1136/ard.2010.134817

Mackworth-Young C. Primary antiphospholipid syndrome: a distinct entity? Autoimmun Rev. 2006;5(1):70-75. DOI: https://doi.org/10.1016/j.autrev.2005.08.001

Agmon-Levin N, Shoenfeld Y.The spectrum between antiphospholipid syndrome and systemic lupus erythematosus.Clin Rheumatol.2014;33(3):293-5. DOI: https://doi.org/10.1007/s10067-014-2486-5